Department of Psychiatry, Yale University, New Haven, CT, USA.
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):468-77. doi: 10.1007/s00259-014-2958-5. Epub 2014 Nov 27.
[(11)C]P943 is a novel, highly selective 5-HT1B PET radioligand. The aim of this study was to determine the test-retest reliability of [(11)C]P943 using two different modeling methods and to perform a power analysis with each quantification technique.
Seven healthy volunteers underwent two PET scans on the same day. Regions of interest (ROIs) were the amygdala, hippocampus, pallidum, putamen, insula, frontal, anterior cingulate, parietal, temporal and occipital cortices, and cerebellum. Two multilinear radioligand quantification techniques were used to estimate binding potential: MA1, using arterial input function data, and the second version of the multilinear reference tissue model analysis (MRTM2), using the cerebellum as the reference region. Between-scan percent variability and intraclass correlation coefficients (ICC) were used to assess test-retest reliability. We also performed power analyses to determine the method that would allow the least number of subjects using within-subject or between-subject study designs. A voxel-wise ICC analysis for MRTM2 BPND was performed for the whole brain and all the ROIs studied.
Mean percent variability between two scans across regions ranged between 0.4 % and 12.4 % for MA1 BPND, 0.5 % and 11.5 % for MA1 BPP, 16.7 % and 28.3 % for MA1 BPF, and between 0.2 % and 5.4 % for MRTM2 BPND. The power analyses showed a greater number of subjects were required using MA1 BPF compared with other outcome measures for both within-subject and between-subject study designs. ICC values were the highest using MRTM2 BPND and the lowest with MA1 BPF in ten ROIs. Small regions and regions with low binding had lower ICC values than large regions and regions with high binding.
Reliable measures of 5-HT1B receptor binding can be obtained using the novel PET radioligand [(11)C]P943. Quantification of 5-HT1B receptor binding with MRTM2 BPND and with MA1 BPP provided the least variability and optimal power for within-subject and between-subject designs.
[(11)C]P943 是一种新型、高选择性的 5-HT1B PET 放射性配体。本研究旨在使用两种不同的建模方法确定 [(11)C]P943 的测试-重测可靠性，并对每种定量技术进行功效分析。
7 名健康志愿者在同一天进行了两次 PET 扫描。感兴趣区域（ROI）为杏仁核、海马体、苍白球、壳核、脑岛、额叶、前扣带回、顶叶、颞叶和枕叶以及小脑。使用动脉输入函数数据的 MA1 和多线性参考组织模型分析（MRTM2）的第二个版本，使用小脑作为参考区域，使用两种多线性配体定量技术来估计结合潜力。使用两次扫描之间的百分比变化和组内相关系数（ICC）来评估测试-重测可靠性。我们还进行了功效分析，以确定使用个体内或个体间研究设计的最少受试者数量的方法。对 MRTM2 BPND 进行全脑和所有研究 ROI 的体素内 ICC 分析。
跨区域的两次扫描之间的 MA1 BPND 的平均百分比变化在 0.4%和 12.4%之间，MA1 BPP 的平均百分比变化在 0.5%和 11.5%之间，MA1 BPF 的平均百分比变化在 16.7%和 28.3%之间，MRTM2 BPND 的平均百分比变化在 0.2%和 5.4%之间。功效分析表明，与其他结局指标相比，个体内和个体间研究设计都需要使用 MA1 BPF 才能获得更多的受试者。在十个 ROI 中，MRTM2 BPND 的 ICC 值最高，而 MA1 BPF 的 ICC 值最低。结合低的小区域的 ICC 值比结合高的大区域的 ICC 值低。
使用新型 PET 放射性配体 [(11)C]P943 可以获得可靠的 5-HT1B 受体结合测量值。使用 MRTM2 BPND 和 MA1 BPP 对 5-HT1B 受体结合进行定量，为个体内和个体间设计提供了最小的变异性和最佳的功效。
Zotero 插件